Debate on the size premium continues; so does analysis of vital healthcare sector

BVWireIssue #107-3
August 17, 2011

On August 25th Jim Harrington (Duff & Phelps) and Ted Israel (Ekhoff Accounting) will join BVR for “The Overlap of Company-Specific Risk and the Size Premium.”  The expert duo will examine new research suggesting that double-counting of some company-specific risk measures may be occurring, particularly if these risks are already embedded in a subject company’s earnings stream.  (Attendees to BVR’s recent webinar “The Diminishing Size Effect and Link to Liquidity Risk” will note that this research may differ from findings by presenters Michael Crain and William Kennedy).  As the debate continues, tune into BVR for continued analysis and update.

BVR’s Online Symposium on Healthcare Valuation continues on August 23rd with “Fair Market Value: Ensuring Compliance within the Life Sciences.”  Featuring a trio of experts from HealthCare Appraisers, Ann Brandt, Jason Ruchaber, and Timothy Smith, this latest installment of our Symposium focuses on recent trends in the government’s oversight of the life sciences industry—including closer scrutiny of company practices and tighter enforcement of regulations—and what it means for your FMV estimate of these complicated firms.

Please let us know if you have any comments about this article or enhancements you would like to see.